Tuesday 17th Flashcards
Following a stroke all patients should be offered
an antiplatelet drug unless the person has an indication for an anticoagulant
Immediately after an ischaemic stroke is confirmed by brain imaging
Aspirin 300 mg daily for 2 weeks should be given immediately
- Following this, clopidogrel 75 mg daily should be given long-term
- OR modified-release dipyridamole alongside low dose aspirin
Antiplatelet: Acute coronary syndrome (medically treated)
1st: Aspirin (lifelong) & ticagrelor (12 months)
2nd: If aspirin contraindicated, clopidogrel (lifelong)
Antiplatelet: Percutaneous coronary intervention
1st: Aspirin (lifelong) & prasurgrel or ticagrelor (12 months)
2nd: If aspirin contraindicated, clopidogrel (lifelong)
Antiplatelet: TIA
1st: Clopidogrel (lifelong)
2nd: Aspirin (lifelong) & dipyridamole (lifelong)
Antiplatelet: Ischaemic stroke
1st: Clopidogrel (lifelong)
2nd: Aspirin (lifelong) & dipyridamole (lifelong)
Antiplatelet: Peripheral arterial disease
1st: Clopidogrel (lifelong)
2nd: Asprin (lifelong)
Cyclizine
H1-receptor antagonist that acts by blocking histamine receptors in the CTZ
- safe to use in pregnancy
- CI: cause a drop in cardiac output and an increase in heart rate. For this reason, caution should be employed in patients with severe heart failure
metoclopramide
Dopamine antagonists
- pro-kinetics and should therefore be avoided in intestinal obstruction
- used with caution in patients with Parkinson’s disease
Motion sickness
1st: hyoscine (e.g. transdermal patch) as being the most effective treatment. Use is limited due to side-effects
2nd: non-sedating antihistamines such as cyclizine or cinnarizine are recommended in preference to sedating preparation such as promethazine
Raised superior vena cava pressure
(e.g. secondary to a bad cough) may cause petechiae in the upper body but would not cause purpura
sumatriptan
5-HT1D receptor agonist
- acute treatment of migraine
ergotamine
partial agonist of 5-HT1 receptors
pizotifen
5-HT2 receptor antagonist
- prophylaxis of migraine attacks
Methysergide
5-HT2 receptor antagonist
- rarely used due to the risk of retroperitoneal fibrosis